- Home
- TLSA vs MEIP Comparison
TLSA vs MEIP Comparison
Compare TLSA & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- MEIP
- Stock Information
- Founded
- TLSA 2013
- MEIP 2000
- Country
- TLSA United Kingdom
- MEIP United States
- Employees
- TLSA N/A
- MEIP N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- MEIP Health Care
- Exchange
- TLSA Nasdaq
- MEIP Nasdaq
- Market Cap
- TLSA 187.0M
- MEIP 153.9M
- IPO Year
- TLSA 2000
- MEIP 2003
- Fundamental
- Price
- TLSA $1.97
- MEIP $4.89
- Analyst Decision
- TLSA
- MEIP
- Analyst Count
- TLSA 0
- MEIP 0
- Target Price
- TLSA N/A
- MEIP N/A
- AVG Volume (30 Days)
- TLSA 555.6K
- MEIP 1.2M
- Earning Date
- TLSA 08-26-2025
- MEIP 09-18-2025
- Dividend Yield
- TLSA N/A
- MEIP N/A
- EPS Growth
- TLSA N/A
- MEIP N/A
- EPS
- TLSA N/A
- MEIP N/A
- Revenue
- TLSA N/A
- MEIP N/A
- Revenue This Year
- TLSA N/A
- MEIP N/A
- Revenue Next Year
- TLSA N/A
- MEIP N/A
- P/E Ratio
- TLSA N/A
- MEIP N/A
- Revenue Growth
- TLSA N/A
- MEIP 33.76
- 52 Week Low
- TLSA $0.63
- MEIP $1.46
- 52 Week High
- TLSA $2.60
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- TLSA 49.01
- MEIP 52.62
- Support Level
- TLSA $1.90
- MEIP $4.62
- Resistance Level
- TLSA $2.53
- MEIP $5.19
- Average True Range (ATR)
- TLSA 0.26
- MEIP 0.43
- MACD
- TLSA -0.05
- MEIP -0.16
- Stochastic Oscillator
- TLSA 12.50
- MEIP 19.57
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.